The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
Subscribe To Our Newsletter & Stay Updated
